ALK and non-small cell lung carcinoma: Regarding ALK-inhibitor-naïve cases, a Phase III study of ALK-p, ALK-inhibitor-naïve, advanced NSCLC has demonstrated that the PFS of brigatinib-treated patients was significantly longer than that of crizotinib-treated patients [23].